Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Dompe' Farmaceutici Spa is currently managing 6 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 5 distinct art units, which indicates that the company's patent applications cover a wide variety of specialized fields. The company is interacting with 6 distinct examiners, meaning that every single pending action is being reviewed by a different official.
The busiest examiner for the company is REDWOOD, CHRISTOPHER EVAN, who is responsible for 1 busiest examiner pending action. Because the 6 pending office actions are spread among different examiners, no single official has a dominant influence over the portfolio's current progress. This distribution requires the company to adapt its prosecution strategy to the individual styles of many different people. Furthermore, the 5 distinct art units involved mean that the company must navigate the specific procedural nuances of different administrative groups within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (17%) |
| §103 only | 2 (33%) |
| Double-patenting + other | 2 (33%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REDWOOD, CHRISTOPHER EVAN | 1 | 0.0% | +0.0% |
| DAHLIN, HEATHER RAQUEL | 1 | 41.1% | +47.5% |
| FORD, VANESSA L | 1 | 38.3% | +38.4% |
| SCHLIENTZ, NATHAN W | 1 | 41.3% | -18.9% |
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 33.3% | +38.9% |
| LEE, ANDREW P | 1 | 48.3% | +23.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18024624 | PEPTIDES ENDOWED WITH ANGIOGENIC ACTIVITY | KONOPELSKI SNAVEL, SARA ELIZABETH | 5d |
| 18843373 | GPR120 AGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | REDWOOD, CHRISTOPHER EVAN | — |
| 18275849 | NGF ISOFORM FOR USE IN THE TREATMENT OF OCULAR PATHOLOGIES | FORD, VANESSA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17800639 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | LEE, ANDREW P | 19d overdue |
| 18024624 | PEPTIDES ENDOWED WITH ANGIOGENIC ACTIVITY | KONOPELSKI SNAVEL, SARA ELIZABETH | 5d |
| 18279708 | CXCL8 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF FOR USE IN THE TREATMENT OF SEIZURES | DAHLIN, HEATHER RAQUEL | 15d |
| 18275849 | NGF ISOFORM FOR USE IN THE TREATMENT OF OCULAR PATHOLOGIES | FORD, VANESSA L | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1674 | 1 |
| 1616 | 1 |
| 1658 | 1 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18843373 | GPR120 AGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | REDWOOD, CHRISTOPHER EVAN | — | §103§112DP | Non-Final OA | — | Pending | Sep 03, 2024 |
| 18279708 | CXCL8 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF FOR USE IN THE TREATMENT OF SEIZURES | DAHLIN, HEATHER RAQUEL | 1629 | §102§103DP | Final Rejection | 15d | Pending | Aug 31, 2023 |
| 18275849 | NGF ISOFORM FOR USE IN THE TREATMENT OF OCULAR PATHOLOGIES | FORD, VANESSA L | 1674 | §102§112 | Non-Final OA | — | Pending | Aug 04, 2023 |
| 18034252 | PHARMACEUTICAL PACKAGES COMPRISING POLYPROPYLENE CONTAINERS AND NGF AQUEOUS FORMULATIONS PACKAGED THEREIN | SCHLIENTZ, NATHAN W | 1616 | §103 | Final Rejection | — | Pending | Apr 27, 2023 |
| 18024624 | PEPTIDES ENDOWED WITH ANGIOGENIC ACTIVITY | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §101§102§103§112 | Non-Final OA | 5d | Pending | Mar 03, 2023 |
| 17800639 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | LEE, ANDREW P | 1691 | §103 | Non-Final OA | 19d overdue | Pending | Aug 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial